Equillium, Inc.

Stage 4 · Declining · week 3

As of Oct 22, 2026, Equillium is in Stage 4, the downtrend phase, now in week 3 (since Oct 7, 2026). It closed at $1.27, 60.3% below its 52-week high and below its 200-day average, which is rising.

$1.27

-10.56% today

$80.5M · Micro cap

Market Neutral — Building

Pro read

Pro

Our read

Declining, below its long-term trend

Setup score

—

Momentum

Steady

Edge

—

Is EQ early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2023-08-16 → 2026-10-22

S4 14w

S2 14w

S4 17w

S2 28w

2023-08-162026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S1 6w → S4 14w → S1 4w → S2 14w → S3 8w → S4 9w → S1 11w → S4 13w → S1 6w → S4 17w → S1 3w → S2 11w → S3 11w → S2 28w → S3 8w → S4 2w current

Total tracked: 165 weeks across 16 stage runs.

EQ among Biotechnology213th of 591 by relative strength

All 591 →

Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	GTBPGT Biopharma, Inc.	Stage 2 · wk 7	99	−22.3%
2	IOVAIovance Biotherapeutics, Inc.	Stage 2 · wk 18	99	+38.8%
3	SLSSELLAS Life Sciences Group, Inc.	Stage 3 · wk 4	99	−1.5%
4	MRNAModerna, Inc.	Stage 2 · wk 17	99	+11.3%
5	TWSTTwist Bioscience Corporation	Stage 2 · wk 39	99	−14.5%
6	KODKodiak Sciences Inc	Stage 2 · wk 4	99	+172.1%
7	ERASErasca, Inc.	Stage 3 · wk 5	99	+0.7%
8	CLYMClimb Bio, Inc.	Stage 3 · wk 3	99	−15.8%
…213	EQEquillium, Inc.	Stage 4 · wk 3	48	−27.4%

vs 52W High

-60.3%

$0.84 lo$3.20 hi

60.3% below 52W high, deep Stage 4 damage

In Stage 4, distance from the 52-week high reflects an ongoing decline, not a discount.

Stage Maturity

Week 3

1w13w26w

Week 3, early Stage 4 decline

How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure. No length of decline marks a bottom on its own.

vs 200 DMA

-38.7%

200 DMA: $2.07 · rising

In Stage 4, the stock is below its 200-day average, the hallmark of a downtrend. Stage analysis waits for that to reverse before buying.

Rel Volume

0.51x

vs 50-day avg

High volume on down days in Stage 4 confirms institutional selling. Low-volume bounces are typical. They lack real buyers and are easy to mistake for reversals.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

-27.4%

-49.0%

-41.5%

YTD

-17.0%

-8.0%

Scan Membership

Breakout Watch

Latest: 2024-02-02

4 appearances in last 60 days. First seen: 2020-02-19.

A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.

Recent Stage Timeline

2026-10-22S4

Wk 3 · Vol 0.51x

2026-10-21S4

Wk 3 · Vol 0.69x

2026-10-20S4

Wk 2 · Vol 1.23x

2026-10-19S4

Wk 2 · Vol 5.58x

2026-10-16S4

Wk 2 · Vol 0.82x

2026-10-15S4

Wk 2 · Vol 0.90x

2026-10-14S4

Wk 2 · Vol 0.46x

2026-10-13S4

Wk 1 · Vol 0.69x

2026-10-12S4

Wk 1 · Vol 0.66x

2026-10-09S4

Wk 1 · Vol 0.90x

2026-10-08S4

Wk 1 · Vol 1.13x

2026-10-07S43→4

Wk 1 · Vol 0.59x

Moving averages & range

50 DMA

$1.88

200 DMA

$2.07

52W High

$3.20

52W Low

$0.84

5D Low

$1.19

Resistance levels (recent highs)

20d High

$1.68

60d High

$2.56

120d High

$3.20

250d High

$3.20

Next resistance

+32.3%

to 20d High

ROE

-59.0%

Profit margin 0.0%

Dividend Yield

0.00%

P/B 1.4

Equillium: quick answers

What stage is Equillium in?

As of Oct 22, 2026, Equillium (EQ) is in Stage 4, the downtrend phase. It entered Stage 4 on Oct 7, 2026 and is in week 3. What the four stages mean

Is Equillium in an uptrend?

No. Equillium is in a Stage 4 downtrend. It trades 38.7% below its 200-day average, which is rising.

How far is Equillium from its 52-week high?

Equillium closed at $1.27 on Oct 22, 2026, 60.3% below its 52-week high of $3.20. Its 52-week low is $0.84.

How has Equillium performed over the past year?

As of Oct 22, 2026, Equillium is down 8.0% over the past year and down 17.0% so far in 2026.

Which sector and industry is Equillium in?

Equillium is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

Equillium, Inc., a clinical-stage biotechnology company, develops therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders in the United States. The company develops EQ504, a novel AhR modulator that is in preclinical-stage for the treatment of ulcerative colitis and lung inflammation diseases. It also develops EQ302, a bi-specific inhibitor of IL-15 and IL-21 formulated for oral delivery for the treatment of celiac diseases. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.